alexa Michael R Clark | OMICS International
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
 

Michael R Clark

Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, United Kingdom

Biography

Mike Clark is a Immunologist and Antibody Engineering Consultant, co-owner & managing director at Clark Antibodies Ltd in University of Cambridg, united kingdo. his Extensive experience of the development of antibody based therapeutics including recombinant and bispecific antibodies. An inventor of the first fully humanised antibody CAMPATH (alemtuzumab) and several other humanised therapeutic antibodies to antigens such as CD3 (TRX4 otelixizumab) and CD4 (TRX1). Alemtuzumab was approved for treatment of B-CLL from 2001 and it has also undergone successful phase III trials in MS and since 2013 it has been approved for use in MS in a number of countries including Europe, Australia and Canada and in the USA from November 2014 under the tradename Lemtrada. his More recent work has concentrated on antibodies with modified Fc properties and some of these modifications have found their way into antibodies such as Tolerex / GSK's otelixizumab, and several of Pfizer's antibodies such as tanezumab, ponezumab, RN316 and RN564. Other modifications have been licensed to companies such as Xencor. In collaboration with the UK NHSBT we have also been investigating the use of a modified antibody to HPA-1a antigen for treatment of feto-maternal allo-immune thrombocytopenia (FMAITP).
 
 

Research Interest
Antibody Engineering, Antibody Therapy, Therapeutic Immunology
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

bornova escort

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

https://www.gaziantepescort.info

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version